FlowPhysix: Precision Thrombectomy Informed by First Principles
FlowPhysix was founded with the vision to set new standards for the treatment of endovascular diseases. The company’s first area of focus is peripheral thrombectomy – where significant performance gaps exist with current thrombectomy systems and physicians continue to seek better solutions for treating their patients. By leveraging the foundational science of fluid flow and through extensive studies of clot morphology and blood flow, the company has developed the FLOWRUNNER™ Aspiration System. This breakthrough system has proven to deliver significant performance advantages over conventional aspiration and stentriever thrombectomy systems.
FlowPhysix (formerly Expanse ICE) was founded in 2022 and spun off from Expanse Medical in April 2024. Guided by engineering rigor, deep clinical insight, and a strong emphasis on foundational science, Expanse Medical is a global powerhouse in vascular innovation and manufacturing.
Board of Directors
Our core leadership represents mastery of every aspect of the medical device industry, from R&D and innovation, through regulatory and manufacturing, to commercialization and management. Their vast experience is the foundation of our success.
FlowPhysix Announces Strategic Partnership with 3Comma for International Distribution of Innovative Thrombectomy Device
FlowPhysix™ Inc, formerly known as Expanse ICE, is pleased to announce a strategic partnership with 3comma Medical / 3comma Medical GmbH who will serve as the international commercial partner for the FLOWRUNNER™ Aspiration System.
Expanse Ice aspiration system receives US FDA clearance for vessels of the peripheral arterial and venous systems
Expanse Ice recently announced that its Ice aspiration system has received 510(k) clearance from the US Food and Drug Administration (FDA).